Introduction
Acute promyelocytic leukemia (APL) is a speci®c subset of acute leukemia (FAB M3) that frequently contains the t(15;17). This translocation results in a balanced rearrangement leading to expression of the fusion transcript, PML/RARa (de TheÂ et al., 1990; Borrow et al., 1990; Longo et al., 1990) . Submicroscopic translocations can occur in APL to yield PML/ RARa expression Ikeda et al., 1994) . Variant translocations exist and also involve RARa rearrangements (Chen et al., 1993; Redner et al., 1996; Wells et al., 1997) . While clinical RA response has not yet been comprehensively analysed in patients with variant translocations, PLZF-RARa expressing APL cases appear refractory to RAtreatment. RA induces complete but transient complete remissions in t(15;17) APL cases through signaling of leukemic cell maturation (Huang et al., 1988; Castaigne et al., 1990; Warrell et al., 1991) . Paradoxically, these clinical responses are tightly coupled to expression of the chimeric transcript, PML/RARa (Miller et al., 1992) .
It is not yet known how PML/RARa interferes directly with normal promyelocyte function, but it is speculated that PML/RARa exerts a dominantnegative eect on the RARa, PML or both pathways (de TheÂ et al., 1991; Kakizuka et al., 1991; Rousselot et al., 1994; Kastner et al., 1992; Grignani et al., 1993) . PML/RARa binds RA with a similar anity as RARa (Nervi et al., 1992) and activates transcription through retinoic acid response elements (RAREs) (reviewed in Mangelsdorf et al., 1994) . Studies reveal that PML/ RARa homodimerizes (Jansen et al., 1995; Perez et al., 1993; Nervi et al., 1992) and heterodimerizes with PML and with RXR (Perez et al., 1993) altering the normal dimerization patterns of these species. Gain of function transfection experiments with PML/RARa are reported in various cell lines and reveal a dominant transcriptional repression of RARa/ RXRa heterodimers (Jansen et al., 1995) , an aberrant localization of PML and RARa (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) and inhibition of dierentiation (Rousselot et al., 1994; Grignani et al., 1993 Grignani et al., , 1995 . In PML/RARa transfected U937 cells, it was reported that a block in RA-mediated differentiation was coincident with a higher growth rate due to reduced apoptosis . In contrast, analysis of apoptosis in NB4 (Lanotte et al., 1991) APL cells, which express PML/RARa and respond to RA-mediated maturation, has shown that RA-treatment of parental NB4 cells leads to maturation without induction of apoptosis (Bruel et al., 1995) . Treatment with another retinoid, 4HPR, does signal apoptosis in these cells (Delia et al., 1993) .
This indicates the potential for apoptosis present in these APL cells, but underscores the need to de®ne better the relationship between PML/RARa expression and apoptosis in promyelocytic leukemia. A critical role for PML/RARa expression in maintaining basal leukemic cell growth is shown through in vitro studies conducted in the NB4 APL cell line where RAtreatment is known to repress proliferation and PML/RARa expression (Lanotte et al., 1991; Yoshida et al., 1996) as well as to signal myeloid leukemic cell maturation. Over-expression of the non-rearranged alleles PML (Mu et al., 1994; Ahn et al., 1995b) or RARa (Ahn et al., 1995b) reduces PML/RARa expression relative to the products of these alleles and signals marked growth suppression. Analysis of RA-resistant NB4 cells identi®ed aberrant expression of PML/RARa in some, but not all isolated clones (Dermime et al., 1993; Duprez et al., 1992; NasonBurchenal et al., 1997) , indicating additional studies are needed to analyse the function of PML/RARa in APL. This view is supported by the ®ndings obtained in transgenic PML/RARa lines where leukemogenesis is triggered in some lines only after a long latency (Early et al., 1996; Grisolano et al., 1997; Brown et al., 1997; He et al., 1997) .
This study sought to assess directly the PML/RARa role in APL using a loss of function strategy complementing prior gain of function approaches. To achieve this, PML/RARa mRNA was targeted using a hammerhead ribozyme engineered to cleave this transcript (Pace et al., 1994) . As a control for antisense eects in these experiments, a non-catalytic ribozyme was engineered with the capacity to hybridize to, but not cleave, PML/RARa mRNA. The ®ndings reported in this study reveal that targeting PML/RARa was accomplished in vivo in NB4 APL cells using episomal-based expression vectors and a previously described selection strategy to regulate expression of potential growth suppressive species (Moasser et al., 1995; Ahn et al., 1995a) .
The targeting of PML/RARa mRNA causes reduced expression of PML/RARa protein and signals marked growth suppression without maturation of these transfectants. This growth suppression is linked to the triggering of apoptosis in PML/ RARa targeted cells. When compared to parental NB4 cells, transfectants expressing the anti-sense control (non-catalytic) ribozyme revealed no appreciable growth or maturation eects. Notably, control cells lacking PML/RARa expression were also transfected with PML/RARa catalytic or noncatalytic ribozymes, and growth and dierentiation eects were not observed in any of these transfectants. Thus, these data using ribozyme-mediated inactivation of PML/RARa in promyelocytic leukemia cells indicate that PML/RARa functions as an anti-apoptotic translocation product. These data also point to the therapeutic potential of PML/RARa cleaving ribozymes in APL.
Results

In vitro cleavage of PML/RARa by self-cleaved ribozymes
To assess the ecacy of the ribozymes released from self-cleaving cassettes, APL 5.0 (an anti-sense noncatalytic control hammerhead ribozyme) and APL 1.1 (a PML/RARa cleaving hammerhead ribozyme) were individually cloned into the pGEM4 plasmid (Promega, Madison, WI) under control of the T7 promoter ( Figure 1a ). These self-cleaving cassette plasmids were digested with EcoRI, and run-o transcripts were synthesized using T7 RNA polymerase (Promega, Madison, WI). As the transcription proceeded, the 5' and the 3' hammerheads folded onto themselves to cleave and release the internal fragment. The transcription reactions were electrophoresed on denaturing 12% polyacrylamide gels and were UV shadowed to visualize the RNA bands. The results are displayed in a photograph depicting the products from the cleavage reaction ( Figure 1b ). There are three major bands in each lane which represent the RNA products of the 5' self-cleavage reaction (95 nt), the RNA products of the Figure 1 In vitro transcription of ribozymes and in vitro cleavage of PML/RARa substrate. The self-cleaving ribozymes are depicted (a). Run-o transcripts were synthesized from the hammerhead ribozymes. As the transcription proceeded, the ribozymes folded onto themselves and cleaved to release the catalytic or non-catalytic ribozyme. The transcription reactions were electrophoresed on a polyacrylamide gel. The gel to the left is a UV shadow of the RNA bands (b). The boxes indicate the ribozyme bands that were excised, gel puri®ed, and used to cleave a 32 P-labeled PML/RARa substrate. The sequence of the APL 1.1 and APL 5.0, ribozymes are shown as they would hypothetically hybridize to PML/RARa mRNA (c). In both APL 1.1 and APL 5.0 there is a 15 nt 5' hybridizing arm, the core (catalytic in APL 1.1 and non-catalytic in APL 5.0), and a 14 nt 3' hybridizing arm. The gel displayed on the right of the ®gure (d) depicts results of in vitro cleavage reactions, with S designating the 760 nt 32 P-labeled PML/RARa substrate, and with P1 designating the major product of cleavage Targeting PML/RARa in promyelocytic leukemia cells K Nason-Burchenal et al 3' cleavage reaction (49 nt) and the released hammerhead ribozymes, which are outlined with boxes. APL 5.0 is 37 nt, and APL 1.1 is 51 nt. The hypothesized intermediates formed before cleavage are depicted in Figure 1c . The cleavage site in the PML/RARa mRNA is indicated with an arrow, with the PML portion of the message underlined. The structure of the hammerhead ribozyme intermediate depicted is APL 1.1, with the indicated nucleotide changes made to render it the non-catalytic APL 5.0. The APL hammerhead bands were excised from the gel and used to cleave 32 P-labeled PML/RARa substrate (760 nt) in a test tube reaction with 30-fold ribozyme excess. The products were electrophoresed on a 4% polyacrylamide gel (Figure 1d ). Uncleaved substrate (S) is the upper band, and the major cleavage product (P1) is indicated. The ®rst lane (C) is a control reaction (no ribozyme). The second lane shows that the noncatalytic ribozyme, APL 5.0, does not cleave the PML/RARa substrate. APL 1.1 catalyzes substantial substrate cleavage, as seen from the prominent P1 band. These results indicate that there is ecient selfcleavage yielding eective, catalytic hammerhead ribozymes. Prior work demonstrated that these ribozymes do not cleave PML, but APL 1.1 can cleave RARa much less eciently than PML/RARa (Pace et al., 1994) .
Transfection of a catalytic ribozyme into NB4 cells decreases PML/RARa protein expression
Protein lysates were isolated from untransfected NB4 cells, NB4 cells transfected with the non-catalytic APL 5.0 ribozyme, and NB4 cells transfected with the catalytic APL 1.1 ribozyme. Transfectants were cultured for 6 days in the increased dose of 300 mg/ml hygromycin. An MTT proliferation assay (Figure 3a ) was performed in conjunction with the protein harvest to correlate immunoblot results with the growth rates of the NB4 transfectants. Figure 2 depicts representative immunoblots for PML/RARa and RARa expression. No appreciable change in PML/RARa expression was noted for APL 5.0 versus APL 1.1 ribozyme transfectants cultured at the 65 mg/ml dosage ( Figure  2 ). However, when cultured in 300 mg/ml hygromycin for 6 days (Figure 2 ), there was a decline in PML/ RARa expression in NB4 cells containing the APL 1.1 ribozyme. A minor reduction in RARa expression was also noted in the APL 1.1 transfectants cultured at the higher hygromycin dosage, as shown in Figure 2 . Due to the rapid triggering of a lethal phenotype in APL 1.1 NB4 transfectants at the 500 mg/ml hygromycin dosage, immunoblot experiments for detection of PML/RARa expression could not be performed at this hygromycin dosage.
Ribozyme-mediated eects on growth and viability
Transfected NB4 cells were maintained in a low dosage (65 mg/ml) of hygromycin. The MTT assay was used to assess eects of the ribozymes on the proliferation rates of the transfected cells. The growth rates were compared when ribozyme-transfected NB4 cells were cultured in the maintenance dose of hygromycin (65 mg/ml), an increased hygromycin dosage (195 mg/ml), a higher dosage (300 mg/ml), or the highest examined dosage (500 mg/ml), as shown in Figure 3 . Preliminary studies in NB4 cells revealed that a ribozyme directed against the same site, but with shorter hybridizing arms with respect to APL 1.1 was much less eective at inhibiting growth (data not shown). As the hygromycin selective pressure was increased, the NB4 cells transfected with the catalytic ribozyme, APL 1.1, grew at a slower rate than cells transfected with the non-catalytic control, APL 5.0. When the hygromycin concentration was increased to 195 mg/ml, the cells transfected with APL 5.0 did not appreciably change their rate of growth, as shown in Figure 3a . In contrast to these NB4 transfectants, in 195 mg/ml hygromycin selection, cells expressing APL 1.1 had a decreased growth rate, although viability was minimally aected as measured on day 6 (Figure 3b ). With higher hygromycin dosages, 300 mg/ ml, the proliferation of APL 5.0 transfected cells was still unchanged and viability was 88% on day 6, while cells expressing APL 1.1 were growth-inhibited and the viability decreased to 69% on day 6 (Figure 3 ). At the 500 mg/ml hygromycin dosage, there was a marked inhibition of growth in transfectants containing the catalytic ribozyme. On day 6 at this hygromycin dosage, viability was 88% in cells with APL 5.0 and 20% in cells containing APL 1.1. Because of the rapid cytotoxicity observed at the highest hygromycin dosage tested for the APL 1.1 transfectants, it was dicult to assess maturation eects at this dosage.
To determine whether the catalytic ribozyme APL 1.1, potentially had non-speci®c cleavage activity that may have mediated this growth suppression, it was Figure 2 Reduction of PML/RARa protein expression in PML/ RARa-cleaving ribozyme transfected NB4 cells depends on the dosage of hygromycin selective pressure used. Western analysis was performed using 50 mg of protein from APL 5.0 or APL 1.1 transfected NB4-S1 cells that were cultured in 65 mg/ml or 300 mg/ml hygromycin for 6 days. The anti-RARa antibody recognizes PML/RARa as indicated by the single arrowhead and RARa depicted by the double arrowheads transfected into the RA-responsive human bronchial epithelial cell line, BEAS-2B (Reddel et al., 1988) . BEAS-2B transfectants were selectable at 20 mg/ml hygromycin. When cultured in the increased dosages of 65 m/ml or 100 mg/ml hygromycin which is known to maximally express cDNAs using these episomal vectors in BEAS-2B derived cells (Ahn et al., 1995a) , neither the growth nor the viability of BEAS-2B cells was Figure 3 (a) MTT proliferation assay and viability of APL 5.0 or APL 1.1 transfected NB4 cells. These transfectants were cultured in 65 mg/ml, 195 mg/ml, 300 mg/ml or 500 mg/ml hygromycin for 6 days and results from each dosage are depicted separately. On days 3 through 6, the MTT assay was performed with the Y axis depicting optical density (OD) of the samples performed on each day depicted on the X axis. (b) On day 6 of the MTT assay displayed in a, viability was assessed by trypan blue exclusion with percentage of viable cells depicted on the Y axis. The ribozyme transfected and the hygromycin selection dosages are provided
aected by the expression of the catalytic ribozyme, APL 1.1 nor the non-catalytic control ribozyme, APL 5.0 (data not shown).
PML/RARa catalytic ribozyme does not induce NB4 myeloid maturation
In response to RA treatment, NB4 cells are growth inhibited and terminally dierentiate into a myeloid lineage (Lanotte et al., 1991) . Whether ribozymemediated growth inhibition and cell death triggered dierentiation by overcoming the inhibitory eects of PML/RARa was assessed by monitoring cell surface expression of the Mo 1 antigen, a myelomonocytic marker of dierentiation, and with the NBT assay of myeloid function. These assays were performed after 6 days of culture in 65 mg/ml, 195 mg/ml or 300 mg/ml hygromycin. Results displayed in Figure 4 reveal that dierentiation is not induced in the PML/RARa cleaving ribozyme-transfected cells. While the positive control cells (NB4 cells treated with 10 76 M RA for 6 days) were 84% NBT positive, none of the ribozyme containing NB4 cells, at any tested dose of hygromycin, showed appreciable NBT positivity. Likewise, 76% of the positive control cells (NB4 cells treated with 10 76 M RA) had an increase in Mo 1 expression over basal levels, while there was minimal increase in Mo 1 expression in the ribozyme-transfected cells at the examined hygromycin dosages. RA-treatment of the APL 5.0 and APL 1.1 NB4 transfectants still signals myeloid maturation of these cells (data not shown).
It is known that in situ staining of NB4 cells with a PML antibody shows a diuse pattern of PML distribution. As NB4 cells dierentiate, typically in response to RA-treatment, a distinct nuclear speckled pattern appears, and these areas of PML localization are designated as nuclear bodies or PODs (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) . To gauge whether any change in PODs are associated with the ribozyme-mediated growth suppressive response in NB4 APL cells, the transfectants were analysed for nuclear body formation after 6 days of culture in 65 mg/ml, 195 mg/ml, or 300 mg/ml hygromycin. The diuse nuclear staining pattern present in undifferentiated NB4 cells was not observed to appreciably change. There was no indication of the reorganization of nuclear bodies in these ribozyme-transfected NB4 cells (data not shown).
Ribozyme mediated induction of apoptosis
Whether cell death in NB4 cells transfected with APL 1.1 was due to induction of apoptosis was measured with a Tdt assay. The assay was performed on cells after culture in 65 mg/ml, 195 mg/ml, or 300 mg/ ml hygromycin for 2, 3, and 4 days ( Figure 5 ). On day 2, in 65 mg/ml hygromycin, NB4 cells transfected with APL 5.0 had a basal level of 1.0% apoptosis, which is comparable to untransfected NB4 cells (data not shown). APL 1.1 had a level of 1.5%. In neither 195 mg/ml nor 300 mg/ml hygromycin was apoptosis induced appreciably in APL 5.0 transfectants. After 3 days in culture, APL 5.0 transfectants exhibited minimal dierences in the percentage of apoptotic cells of the three tested dosages of hygromcyin: 65 mg/ ml (2.6%); 195 mg/ml (2.1%); and 300 mg/ml (2.5%). APL 1.1 NB4 transfectants had an increase in apoptosis, not only higher than on day 2, but also as Figure 4 Analysis of dierentiation states of parental NB4-S1 (control) cells and APL 5.0 or APL 1.1, transfected NB4 cells. Parental NB4-S1 cells were cultured in the absence (RA7) or presence (RA+) of 10 76 M RA for 6 days. Ribozyme transfected cells were cultured in 65 mg/ml, 195 mg/ml or 300 mg/ml hygromycin for 6 days. The NBT assay was performed on day 6 to asess functional myeloid maturation. The results are depicted by black diamonds, and the scale of percentage of cells that are NBT positive is on the right Y axis. On the same day, cells derived from the cultures used for the NBT assay were analysed for the expression of Mo 1, a cell surface antigen that is induced as these myeloid cells mature. These results are depicted by gray bars with the scale of percentage of cells that have increased Mo 1 expression displayed on the left Y axis Figure 5 Induction of apoptosis in ribozyme transfected NB4-S1 cells. Cells transfected with APL 5.0 or APL 1.1 were cultured in 65 mg/ml, 195 mg/ml or 300 mg/ml hygromycin for 2, 3 and 4 days. The Y axis depicts per cent apoptosis. This ®gure indicates there is an increased signaling of apoptosis following increased selective pressure for expression of these ribozymes achieved at higher hygromycin dosages. The apoptotic changes observed for the APL 1.1 transfectant are statistically signi®cant, as discussed in the Results section Targeting PML/RARa in promyelocytic leukemia cells K Nason-Burchenal et al the hygromycin dosages increased from 65 mg/ml (3.1%) to 195 mg/ml (7.4%) and 300 mg/ml (10.2%). By day 4, there was still no appreciable change in apoptotic cells containing APL 5.0 at dierent doses: 1.6% (65 mg/ml) 1.6% (195 mg/ml) and 2.6% (300 mg/ ml). In contrast, APL 1.1 cells increased the percentage of apoptosis from 3.0% (65 mg/ml) to 5.5% (195 mg/ ml) and then to 13.4% at 300 mg/ml ( Figure 5 ). This change at the 300 mg/ml hygromycin dosage between APL 5.0 versus APL 1.1 is highly signi®cant (P40.001 using the Kolmogorov-Smirnov statistical analysis) (Young, 1977) . Maintenance of the transfected NB4 cells in 65 mg/ml hygromycin had no appreciable eect on the percentage of apoptosis. Transfectants were cultured without exposure to hygromycin for 1 week, and then a Tdt assay was performed comparing the percentage of apoptosis in those cells with cells continually maintained in 65 mg/ml hygromycin. There was no observed dierence in the percentage of apoptosis detected between these two groups (data not shown).
Discussion
APL presents a clinical paradox. While the t(15;17) balanced rearrangement results in the chimeric product, PML/RARa, in APL cells, bene®cial clinical response to RA-treatment is linked to expression of PML/RARa. This study was undertaken to address this paradox by targeting directly PML/RARa expression in APL cells using an episomal vector-based transfection strategy and a hammerhead ribozyme engineered to cleave PML/RARa in vitro. Findings presented in this study reveal a clearer understanding of the role of PML/RARa in APL cells. The NB4 APL cell line (Lanotte et al., 1991) was used as a model for study. These cells express PML/RARa mRNA and protein. Before RA-treatment, these cells exhibit an immature myeloid phenotype with unlimited growth potential in culture. After RA-treatment, these cells terminally dierentiate into a mature myeloid phenotype. Thus, this in vitro cell system re¯ects key biologic features of APL observed in the retinoid sensitivity of clinical APL cases: maturation induction by RAtreatment is linked to decreased growth potential of PML/RARa expressing leukemic cells. The major ®ndings of this study include: (1) ribozyme-mediated targeting of PML/RARa mRNA leads to reduced expression of PML/RARa protein and this signals repressed growth and cytotoxicity but not maturation of transfected NB4 cells; (2) this cytotoxicity is due, at least partially, to the triggering of apoptosis when PML/RARa expression is reduced; and (3) these eects depend on the expression of catalytic, PML/RARa cleaving ribozymes but not non-catalytic, anti-sense control ribozymes. These ®ndings, when coupled with the observed cytotoxicity of APL 1.1 NB4 transfectants at the highest hygromycin dosage tested (500 mg/ml), indicate an optimal level of PML/RARa expression is required to maintain basal leukemic cell growth.
The ®ndings presented in this study complement prior work in this ®eld. While PML/RARa binds retinoic acid with a similar anity as does RARa (Nervi et al., 1992) , PML/RARa exhibits an altered transcriptional activation pro®le (de TheÂ et al., 1991; Kakizuka et al., 1991; Kastner et al., 1992) . Prior work implicated PML/RARa as functioning as a dominantnegative receptor with inhibitory eects on RARa, PML, or both pathways (de TheÂ et al., 1991; Kakizuka et al., 1991; Rousselot et al., 1994; Kastner et al., 1992; Grignani et al., 1993 Grignani et al., , 1995 . Gain of function studies revealed over-expression of PML/RARa in several cell contexts led to altered transcriptional activation (Jansen et al., 1995) , aberrant nuclear localization of PML as compared to wild-type expression patterns (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) , and antagonism of RA-mediated dierentiation in leukemic cells (Rousselot et al., 1994; . Transgenic lines expressing PML/ RARa (Early et al., 1996; Grisolano et al., 1997; Brown et al., 1997; He et al., 1997) exhibit abnormal myeloid function and after a long latency, a subset of PML/RARa expressing transgenic mice develop leukemia (Grisolano et al., 1997; Brown et al., 1997; He et al., 1997) . RA-treatment of these transgenic lines can at least partially reverse the eects of PML/RARa. Thus, studies using myeloid leukemic cell lines and transgenic models indicate the inhibitory eect of PML/RARa on myeloid function.
Few studies antagonized PML/RARa function in APL cells using gain of function strategies. Overexpression of PML/RARa is not yet reported in NB4 APL cells, perhaps due to toxic eects of PML/RARa. However, over-expression of the non-rearranged alleles PML and RARa has been achieved. When PML overexpression was engineered in NB4 cells, growth suppression was observed (Mu et al., 1994; Ahn et al., 1995b) . When RARa was over-expressed in these cells, growth suppression was also signaled, but retinoid maturation response was enhanced (Ahn et al., 1995b) . These studies conducted in the NB4 APL cell line are consistent with an inhibitory role for PML/ RARa which is antagonized through reduction in PML/RARa expression due to increased expression of the products of the non-rearranged alleles: PML or RARa. These ®ndings suggested a loss of function approach to target directly PML/RARa expression would signal major growth or dierentiation eects in APL cells. Even in the established APL cell line, NB4, this is shown to be the case in the experiments reported in this study.
This study extends previous work by antagonizing PML/RARa function through reducing its expression in APL cells. This was accomplished using a hammerhead-ribozyme engineered to target PML/RARa transcripts in vitro and by introducing this catalytic ribozyme into NB4 APL cells using an episomal vector that allows regulated expression of these ribozymes. The ®ndings reported here reveal that catalytic activity of the PML/RARa cleaving ribozyme (Pace et al., 1994) was preserved even when self-cleaving casssettes (Taira et al., 1991) in these episomal vectors were used to express this ribozyme, as shown in Figure 1 . As a control, the APL 5.0 ribozyme, containing one base pair deletion and a one base pair conversion, yields a ribozyme which may hybridize to PML/RARa mRNA but does not cleave this transcript. It is notable that immunoblot analysis for APL 1.1 transfectants could not be peformed at the highest hygromycin dosage examined due to the rapid triggering of a lethal phenotype. It is hypothesized this lethality is due to Targeting PML/RARa in promyelocytic leukemia cells K Nason-Burchenal et al an even greater reduction of PML/RARa expression acheived than observed at lower hygromycin dosages tested. A minor decline in RARa protein expression was observed in the APL 1.1 transfectants cultured in hygromycin dosages greater than 65 mg/ml (Figure 2 and data not shown). While this decline might contribute to the growth suppressive eect of this ribozyme, that RARa null mice do not exhibit myeloid cell defects (Lufkin et al., 1993) argues against this change in RARa gene expression as responsible for the biologic eects reported here using hammerhead ribozymes that target PML/RARa. Also consistent with this viewpoint is the ®nding that a dominantnegative RARa confers retinoid resistance in myeloid leukemic cells (Collins et al., 1990) and abnormal growth and dierentiation to myeloid cells (Tsai and Collins, 1993; Tsai et al., 1994) . This antagonism of RARa function leads to eects that dier from that observed with APL 1.1 transfected NB4 cells. It is worth noting that the growth and maturation eects observed with the transfected ribozyme APL 5.0 did not appreciably dier from that observed in the parental NB4 cells used in this study. Thus, the observed growth suppressive and apoptotic eects seen with APL 1.1 transfectants are consistent with the view that the observed biologic eects are due to the catalytic activity of this ribozyme. This view is supported by ®ndings demonstrating that the biologic eects observed for this catalytic ribozyme are linked to the reduced expression of PML/RARa. Since APL 1.1 transfectants exhibit growth suppression and trigger apoptosis in NB4 cells, these ®ndings indicate a critical basal level of PML/RARa expression is needed to maintain NB4 APL cell growth. These ®ndings indicate that reducing levels of PML/RARa can unmask the anti-apoptotic eects of this translocation product. Since targeting of PML/RARa is accomplished in NB4 APL cells, this cellular reagent may prove useful to evaluate interactions between the histone deacetylase complex and PML/RARa that contribute to the retinoid response of these leukemic cells (Lin et al., 1998; Grignani et al., 1998) .
It is interesting to note that apoptosis is signaled following pharmacologic treatments of NB4 APL or other cells engineered to express PML/RARa. These include arsenic trioxide (Chen et al., 1996) or 4HPR (Delia et al., 1993) treatments and GM-CSF or growth factor deprivation (Rogaia et al., 1995; Fu et al., 1995) . While RA or arsenic trioxide treatments can alter PML/RARa or PML expression (Yoshida et al., 1996; Chen et al., 1996) , these agents likely exhibit additional and pleiotropic eects on gene expression or growth control pathways that are not signaled by ribozyme-mediated catalysis of PML/RARa. The speci®city provided by ribozyme-mediated PML/ RARa catalysis aords an opportunity to assess the direct eects of reducing PML/RARa expression on APL cell growth, dierentiation, or apoptosis. PML/ RARa expression is repressed and apoptosis is not induced by RA-treatment of an NB4 cell line derived to be retinoid resistant through mutagenization and selection in RA (Dermime et al., 1993) . That apoptosis is not induced by RA-treatment of these retinoid resistant NB4 cells having repressed PML/ RARa expression might be due to the mutagenization process which led to changes in gene expression or function that oppose the apoptosis signals typically generated by reducing PML/RARa expression. Consistent with this interpretation is our ®nding that ribozyme-mediated targeting of a mutated PML/ RARa present in a retinoid resistant NB4 APL cell line also triggers apoptosis without inducing maturation of obtained transfectants (Nason-Burchenal et al., in press ). This result and those reported in this study indicate that apoptotic and maturation signals are distinct.
The ®nding that antagonism of function of an oncogenic translocation product leads to triggering of apoptosis has precedence. It is previously reported that over-expression of a dominant-negative suppressor of the fusion protein E2A-HLF antagonizes leukemogensis through signaling of apoptosis (Inaba et al., 1996) . The current study extends this work by showing that catalytic reduction of PML/RARa expression also leads to an anti-leukemogenic eect through the triggering of apoptosis. A question remaining is how this reduced PML/RARa expression signals apoptosis. Which`down-stream' targets are aected by repressing PML/RARa expression need to be identi®ed. Few studies have found down-stream targets of translocation products that could mediate transformation. In chronic myelogenous leukemia, the tyrosine kinase transforming activity of bcr/abl is aected through antagonism of down-stream ras or myc pathways (Goga et al., 1995; Sawyers et al., 1992) . In other leukemic cells, fas is shown as involved in the observed cell death program (reviewed in Nagata, 1997) . Whether the PML/RARa-mediated antagonism of apoptosis uses these or other pathways needs to be discerned. Work by others has shown, in NB4 cells, that maturation and apoptotic events can be dissociated (Bruel et al., 1995) . This view is borne out in the present study.
An unusual aspect of this study is that the agent used to antagonize PML/RARa function, a hammerhead ribozyme, has therapeutic potential in the treatment of APL. That engineered over-expression of the catalytic but not the non-catalytic PML/RARa targeted ribozymes triggers an anti-leukemogenic eect raises the prospect that similar ®ndings will be observed in de novo cultured APL cells. If similar anti-leukemogenic eects are observed in other established APL cell lines or in fresh APL cells derived directly from patients, perhaps anti-leukemic eects will be observed even in the clinical setting. While the delivery of therapeutic ribozymes to APL cells in patients represents a major clinical challenge, PML/RARa cleaving ribozymes may have a therapeutic role in purging leukemic cells present in harvested bone marrow specimens. The recently reported PML/ RARa transgenes (Early et al., 1996; Grisolano et al., 1997; Brown et al., 1997; He et al., 1997) may prove useful to evaluate the therapeutic activity of these PML/RARa cleaving ribozymes. While this possibility is the subject of future work, the current study highlights a speci®c function in APL cells for the PML/RARa translocation product: antagonism of apoptosis. It is interesting to note that the targeting of PML/RARa discriminates between growth and dierentiation programs in these leukemic cells, consistent with prior work in this ®eld (Bruel et al., 1995) . It may be viewed as surprising that persistent expression of PML/RARa is required to maintain basal leukemic cell growth. Yet, these ®ndings set the stage for use of PML/RARa cleaving ribozymes as pharmacologic tools to discover down-stream signals engaged by this translocation product to cause leukemia.
Materials and methods
Ribozymes and vector
Ribozymes used in this study were modi®ed versions of previously described hammerhead ribozymes (Pace et al., 1994) . Ribozyme 1.1 is a 14 nt longer version of ribozymes 1.18 that was reported previously (Pace et al., 1994) and is targeted to the same site on the PML/RARa mRNA as 1.18. The non-catalytic APL 5.0 is identical to APL 1.1 except for an A to C conversion and a G deletion, both in the catalytic core. DNA oligonucleotides corresponding to each strand of each ribozyme were synthesized, annealed and ligated into the self-cleaving cassette. Each self-cleaving cassette containing the desired ribozyme was then subcloned into the episomal vector Eboplpp at the HindIII/NotI sites. The Eboplpp vector, containing the hygromycin resistance gene for drug selection, was used to transfect these hammerhead ribozymes using the reported selection procedure to regulate expression of potential growth suppressive species (Ahn et al., 1995b; Moasser et al., 1995) .
Self-cleavage and in vitro cleavage
The self-cleaving cassettes containing a 5' and a 3' hammerhead ribozyme were cloned into the pGEM-4 plasmid (Promega, Madison, WI, USA) at the EcoRI site (Taira et al., 1991) under the control of the T7 promoter. These ribozyme constructs were digested with EcoRI and run-o transcripts were made using T7 polymerase. As the transcription proceeded, the 5' and the 3' hammerheads folded onto themselves and cleaved to release the internal fragment, the active ribozyme. The transcription reactions were electrophoresed on denaturing 12% polyacrylamide gels, and the gels were UV shadowed to visualize the RNA bands. The APL ribozyme bands were isolated from the gel, puri®ed, and used to cleave the PML/RARa substrate (760 nt) in a 2 h test tube reaction, as previously described (Pace et al., 1994) . The substrate and cleavage products were electrophoresed on a 4% polyacrylamide gel and cleavage was quanti®ed by phosphorimager and analysed with Molecular Dynamics ImageQuant software.
Cell lines and culture conditions
NB4 cells (Lanotte et al., 1991) , a human APL cell line containing the t(15;17) and expressing PML/RARa were a gift of Dr M Lanotte (INSERM, France). A retinoic acid sensitive NB4 clone, designated NB4-S1, was used in these studies, as previously described (Nason-Burchenal et al., 1997) . The NB4-S1 response to RA is similar to that of the parental NB4 line. These cells were cultured in RPMI containing 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine, with 10% fetal calf serum. Post-selection, ribozyme transfected cells were maintained in RPMI supplemented with 65 mg/ml hygromycin. BEAS-2B cells are a human bronchial epithelial cell line (Reddel et al., 1988) derived following an adenovirus 12-SV40 virus hybrid infection and were a gift of Dr Curtis Harris, Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health. These cells were cultured with LHC-9 medium (Bio¯uids, Rockville, MD, USA), supplemented with 10 ng/ml epidermal growth factor (Bio¯uids, Rockville, MD) on plates pre-treated with a mixture of ®bronectin, vitrogen 100 and bovine serum albumin (BSA).
Transfections
NB4-S1 cells (5610 6 ) were washed once, then resuspended in 48C phosphate-buered saline (PBS) (Ca 2+ /Mg 2+ free) and placed in a Gene Pulser Cuvette (Bio-Rad, Hercules, CA). Twenty mg of plasmid DNA were added to each cuvette and mixed. Cells were electroporated at 0.3 kV and 25 mF. BEAS-2B cells were transfected with LipofectA-MINE, as per manufacturer's recommendations (Life Technologies, Gaithersburg, MD, USA).
Protein isolation, Western analysis and antibodies
In brief, 10 7 cells were pelleted, resuspended in 1 ml of 48C RIPA lysis buer (150 mM NaCl+50 mM Tris pH 8.0+1% NP-40+0.5% deoxycholate+0.1% SDS+0.5 mg aprotinin, leupeptin, pepstatin, antitrypsin, chromostatin+1 mM phenylmethylsulfanyl¯uoride) and then incubated at 48C for 30 min. The samples were centrifuged at 12 000 r.p.m. for 2 min at 48C, and the supernatant was stored on ice. Protein concentrations were assessed with the Bradford assay and 50 mg protein/lane were electrophoresed through a 10% SDS-polyacrylamide gel. The protein was electrotransferred from the gel to supported nitrocellulose (Amersham International, England). The ECL Western blotting protocol and kit (Amersham International, England) were used for antibody labeling and detection. The membranes were exposed to XAR Kodak photographic ®lm for the appropriate time optimized for each antibody. On each day of the MTT assay (Denizot and Lang, 1986) , 100 ml of suspended cells were removed from each culture and placed in triplicate into wells of a 96-well plate. Fifty mg of MTT were added and this mix was incubated for 4 h at 378C, 5% CO 2 in an humidi®ed atmosphere. After incubation, 100 ml of 0.04 N HCl in 2-propanol were mixed thoroughly into each well. Plates were read on a Molecular Devices microplate reader at the wavelength 570 nm with a reading at 650 nm subtracted for background. Triplicate readings for each sample were averaged. Trypan blue (Sigma Chemical Company, Saint Louis, MO) staining was used to assess for viability.
Immunophenotypic staining
Cells were resuspended at 10 7 cells/ml in PBS containing 1% BSA. For each sample, 10 6 cells (100 ml) were added to each of two tubes. Cells were incubated at 48C61 h in saturating concentrations of either¯uorescein isothiocyanate (FITC) labeled murine IgM antibody (isotopic control) or the FITC labeled mouse anti-human monoclonal antibody, Mo 1 (Coulter Immunology, Miami, FL, USA). Cells were washed twice with PBS/ 1% BSA and resuspended in 500 ml 0.5% paraformaldehyde (Fisher Scienti®c, Spring®eld, NJ, USA). Analysis was performed with a FACScan (Becton Dickinson, Franklin Lakes, NJ) and measurements contained a minimum of 5610 3 cells.
Nitroblue tetrazolium (NBT) reduction assay
For each assay, 200 mg NBT solution (Sigma Chemical Company, Saint Louis, MO, USA) 10 5 cells and 100 ng phorbol 12-myristate 13-acetate (PMA) (Sigma Chemical Company, Saint Louis, MO, USA) were mixed thoroughly. Samples were incubated at 378C for 15 min then at room temperature for 15 min and 0.1 ml of cells of each sample was cytospun, ®xed in methanol and stained with Safranin-O (Fisher Scienti®c, Spring®eld, NJ, USA). A minimum of 100 cells were scored microscopically as NBT negative or positive (blue).
Terminal deoxynucleotidyl transferase (Tdt) assay
For each transfectant, 10 5 cells were cultured in 65 mg/ml, 195 mg/ml or 300 mg/ml hygromycin (Boehringer Mannheim, Indianapolis, IN, USA). For ®xation, 10 6 cells were centrifuged, resuspended in 2 ml of 1% formaldehyde, incubated on ice for 15 min, washed in PBS, and resuspended in 2 ml of 70% ethanol. To perform this assay, cells were centrifuged, rehydrated in 5 ml PBS and pelleted. This pellet was resuspended in 50 ml Tdt reaction buer (40 mM cacodylate buer+2.5 mMCoCl 2 +7.5 U Tdt enzyme) (Boehringer Manneheim, Indianapolis, IN, USA) plus 0.5 nM biotin dUTP (Boehringer Manheim, Indianapolis, IN, USA) and incubated for 30 min at 378C. After incubation, 5 ml of PBS were added, and the cells were centrifuged. The pellet was resuspended in 100 ml staining buer (46SSC+0.1% Triton X-100+5% dry milk+25 mḡ uoresceinated avidin) and incubated for 30 min at room temperature in the dark. A wash solution of 5 ml PBS+0.1% Triton X-100 was added, and the sample was centrifuged. The cells were washed again and ®nally resuspended in 0.5 ml propidium iodide stain (5 mg/ml propidium iodide+0.1% RNAseA), incubated overnight at room temperature, and stored at 48C. Samples were analysed on a FACScan (Becton Dickinson, Franklin Lakes, NJ).
